791 related articles for article (PubMed ID: 28274850)
21. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.
Charlton M; Gane E; Manns MP; Brown RS; Curry MP; Kwo PY; Fontana RJ; Gilroy R; Teperman L; Muir AJ; McHutchison JG; Symonds WT; Brainard D; Kirby B; Dvory-Sobol H; Denning J; Arterburn S; Samuel D; Forns X; Terrault NA
Gastroenterology; 2015 Jan; 148(1):108-17. PubMed ID: 25304641
[TBL] [Abstract][Full Text] [Related]
22. Successful sofosbuvir-based therapy in HIV/hepatitis C virus coinfected liver transplant recipients with recurrent hepatitis C virus infection.
Grant JL; Hawkins C; Brooks H; Palella FJ; Koppe SW; Abecassis MM; Stosor V
AIDS; 2016 Jan; 30(1):93-8. PubMed ID: 26731756
[TBL] [Abstract][Full Text] [Related]
23. Interleukin 28B gene polymorphisms in hepatitis C virus-related cryoglobulinemic vasculitis.
Sansonno D; Russi S; Serviddio G; Conteduca V; D'Andrea G; Sansonno L; Pavone F; Lauletta G; Mariggiò MA; Dammacco F
J Rheumatol; 2014 Jan; 41(1):91-8. PubMed ID: 24293567
[TBL] [Abstract][Full Text] [Related]
24. Virologic, Clinical, and Immune Response Outcomes of Patients With Hepatitis C Virus-Associated Cryoglobulinemia Treated With Direct-Acting Antivirals.
Bonacci M; Lens S; Londoño MC; Mariño Z; Cid MC; Ramos-Casals M; Sánchez-Tapias JM; Forns X; Hernández-Rodríguez J
Clin Gastroenterol Hepatol; 2017 Apr; 15(4):575-583.e1. PubMed ID: 27725289
[TBL] [Abstract][Full Text] [Related]
25. A Closing Chapter: Hepatitis C Genotype 3 Elimination in Liver Transplant; Sofosbuvir/Daclatasvir in a Hard-to-Treat Population.
Teegen EM; Globke B; Schott E; Pratschke J; Eurich D
Exp Clin Transplant; 2018 Feb; 16(1):61-67. PubMed ID: 29137590
[TBL] [Abstract][Full Text] [Related]
26. INF-free sofosbuvir-based treatment of post-transplant hepatitis C relapse - a Swedish real life experience.
Castedal M; Segenmark M; Cederberg S; Skoglund C; Weiland O
Scand J Gastroenterol; 2017 May; 52(5):585-588. PubMed ID: 28270038
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness and cost of hepatitis C virus cryoglobulinaemia vasculitis treatment: From interferon-based to direct-acting antivirals era.
Cacoub P; Vautier M; Desbois AC; Lafuma A; Saadoun D
Liver Int; 2017 Dec; 37(12):1805-1813. PubMed ID: 28467688
[TBL] [Abstract][Full Text] [Related]
28. Anti-E1E2 antibodies status prior therapy favors direct-acting antiviral treatment efficacy.
Virlogeux V; Berthillon P; Bordes I; Larrat S; Crouy S; Scholtès C; Pradat P; Maynard M; Zoulim F; Leroy V; Chemin I; Trépo C; Petit MA
Clin Res Hepatol Gastroenterol; 2018 Sep; 42(4):313-318. PubMed ID: 29551607
[TBL] [Abstract][Full Text] [Related]
29. Colitis during new direct-acting antiviral agents (DAAs) therapy with sofosbuvir, simeprevir and ribavirin for genotype 1b hepatitis C.
Izzo I; Zanotti P; Chirico C; Casari S; Villanacci V; Salemme M; Biasi L; Festa E; Castelli F
Infection; 2016 Dec; 44(6):811-812. PubMed ID: 27311809
[TBL] [Abstract][Full Text] [Related]
30. Sustained response to interferon-alpha or to interferon-alpha plus ribavirin in hepatitis C virus-associated symptomatic mixed cryoglobulinaemia.
Calleja JL; Albillos A; Moreno-Otero R; Rossi I; Cacho G; Domper F; Yebra M; Escartín P
Aliment Pharmacol Ther; 1999 Sep; 13(9):1179-86. PubMed ID: 10468699
[TBL] [Abstract][Full Text] [Related]
31. Reconstitution of T follicular helper-humoral immune axis with elimination of hepatitis C virus.
Khanam A; Kottilil S; Wilson E
Sci Rep; 2020 Nov; 10(1):19924. PubMed ID: 33199783
[TBL] [Abstract][Full Text] [Related]
32. Clinical decompensation after achieving SVR with sofosbuvir, daclatasvir and ribavirin in a patient with recurrent HCV post-liver transplant.
Kalafateli M; Dusheiko G; Manousou P
J Gastrointestin Liver Dis; 2015 Jun; 24(2):257-8. PubMed ID: 26114189
[No Abstract] [Full Text] [Related]
33. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial.
Forns X; Lawitz E; Zeuzem S; Gane E; Bronowicki JP; Andreone P; Horban A; Brown A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; Scott J; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
Gastroenterology; 2014 Jun; 146(7):1669-79.e3. PubMed ID: 24602923
[TBL] [Abstract][Full Text] [Related]
34. Long-Term Outcomes of Patients With HCV-Associated Cryoglobulinemic Vasculitis After Virologic Cure.
Bonacci M; Lens S; Mariño Z; Londoño MC; Rodriguez-Tajes S; Sánchez-Tapias JM; Ramos-Casals M; Hernández-Rodríguez J; Forns X
Gastroenterology; 2018 Aug; 155(2):311-315.e6. PubMed ID: 29705529
[TBL] [Abstract][Full Text] [Related]
35. Simeprevir and sofosbuvir for treatment of chronic hepatitis C infection.
Childs-Kean LM; Hand EO
Clin Ther; 2015 Feb; 37(2):243-67. PubMed ID: 25601269
[TBL] [Abstract][Full Text] [Related]
36. Antiviral therapy for HCV in hemophilia A patients with HIV-1 co-infection.
Xiao H; Chen J; Wang J; Li J; Yang F; Lu H
Medicine (Baltimore); 2019 Jul; 98(30):e16524. PubMed ID: 31348267
[TBL] [Abstract][Full Text] [Related]
37. Follicular helper T cell and memory B cell immunity in CHC patients.
Liu Y; Ji H; Zhao P; Yan H; Cai Y; Yu L; Hu X; Sun X; Jiang Y
J Mol Med (Berl); 2019 Mar; 97(3):397-407. PubMed ID: 30666346
[TBL] [Abstract][Full Text] [Related]
38. Antiviral therapy of symptomatic HCV-mixed cryoglobulinemia after liver transplant: case report and literature review.
Francesca Donato M; Banfi G; Cresseri D; Battista Fogazzi G; Martin P; Messa P; Fabrizi F
Int J Artif Organs; 2013 May; 36(5):367-72. PubMed ID: 23446762
[TBL] [Abstract][Full Text] [Related]
39. A prospective study of T- and B-lymphocyte subpopulations, CD81 expression levels on B cells and regulatory CD4(+) CD25(+) CD127(low/-) FoxP3(+) T cells in patients with chronic HCV infection during pegylated interferon-alpha2a plus ribavirin treatment.
Soldevila B; Alonso N; Martínez-Arconada MJ; Morillas RM; Planas R; Sanmartí AM; Martínez-Cáceres EM
J Viral Hepat; 2011 Jun; 18(6):384-92. PubMed ID: 20487258
[TBL] [Abstract][Full Text] [Related]
40. Sofosbuvir and simeprevir without ribavirin effectively treat hepatitis C virus genotype 1 infection after liver transplantation in a two-center experience.
Jackson WE; Hanouneh M; Apfel T; Alkhouri N; John BV; Zervos X; Zein NN; Hanouneh IA
Clin Transplant; 2016 Jun; 30(6):709-13. PubMed ID: 27019204
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
